CSIR CIMAP AROMA | Compound Details

Butyl 4-hydroxybenzoate Details

: IUPAC Name

Butylp-hydroxybenzoate

:Chemical Class

:CAS Registry Number

94-26-8

:Description

:Fragrance Type

fermented fruit??????

Physical and Chemical properties

PUBCHEM ID	7184
Molecular Weight (g/mol)	194.233
Molecular Formula	C11H14O3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	5
IUPAC Name	Butylp-hydroxybenzoate
Canonical SMILES	CCCCOC(=O)c1ccc(O)cc1
PUBCHEM IUPAC INCHIKEY	QFOHBWFCKVYLES-UHFFFAOYSA-N
Solubility Level	3
Vapour Pressure

Absorption and Metabolism information

XLOGP3 AA	NA
CACTVS TPSA	52.32
BBB Level	2
Absorption Level	0
EXT PPB#Prediction	0
AlogP98	2.772
EXT CYP2D6#Prediction	0

Toxicological Information

Mouse Female FDA	Multi-Carcinogen
Mouse Male FDA	Multi-Carcinogen
Rat Female FDA	Single-Carcinogen
Rat Male FDA	Multi-Carcinogen
Ames Prediction	Non-Mutagen
Developmental / Reproductive Toxicity	Toxic
Rat Oral LD50	2.33627
Ocular Irritancy	None
Hepatotoxic#Prediction	0
Effected Human Genes	NA

Ecological Information

Aerobic Biodegradability Prediction	Degradable

Hazard(s) Identification

Physical hazards	not classified
Health hazards	Mild
Environmental hazards	not classified

About Table Headings

Compound Biological Activity

Serial No.	Cas No	Gene Symbol	Organism	Interaction	Interaction Actions	PubMed Id
1	94-26-8	ABAT	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA	affects^cotreatment\|increases^expression	25607892
2	94-26-8	ACAN	Mus musculus	butylparaben results in decreased expression of ACAN mRNA	decreases^expression	28527915
3	94-26-8	ACTN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA	affects^cotreatment\|decreases^expression	25607892
4	94-26-8	ADAM17	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	affects^cotreatment\|decreases^expression	25607892
5	94-26-8	ADAM17	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	affects^cotreatment\|increases^expression	25607892
6	94-26-8	ADIPOQ	Homo sapiens	butylparaben results in increased expression of ADIPOQ mRNA	increases^expression	22956630
7	94-26-8	ADIPOQ	Mus musculus	2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]	decreases^reaction\|increases^expression	22956630
8	94-26-8	ADIPOQ	Mus musculus	2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]	decreases^reaction\|increases^expression	22956630
9	94-26-8	ADIPOQ	Mus musculus	butylparaben promotes the reaction [Dexamethasone results in increased expression of ADIPOQ mRNA]	increases^expression\|increases^reaction	22956630
10	94-26-8	ADIPOQ	Mus musculus	Mifepristone inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]	decreases^reaction\|increases^expression	22956630
11	94-26-8	ALPL	Mus musculus	butylparaben results in decreased expression of ALPL mRNA	decreases^expression	28527915
12	94-26-8	ALPL	Mus musculus	NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]	decreases^expression\|increases^reaction	28527915
13	94-26-8	ALPL	Mus musculus	PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]	decreases^expression\|increases^reaction	28527915
14	94-26-8	AR	Rattus norvegicus	butylparaben binds to AR protein	affects^binding	20371976
15	94-26-8	AR		[butylparaben co-treated with propylparaben] promotes the reaction [isobutyl-4-hydroxybenzoate inhibits the reaction [Metribolone results in increased activity of AR protein]]	affects^cotreatment\|decreases^reaction\|increases^activity\|increases^reaction	20132345
16	94-26-8	BDNF	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA	affects^cotreatment\|decreases^expression	25607892
17	94-26-8	BGLAP	Mus musculus	butylparaben results in decreased expression of BGLAP mRNA	decreases^expression	28527915
18	94-26-8	BSN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA	affects^cotreatment\|decreases^expression	25607892
19	94-26-8	CACNA1A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA	affects^cotreatment\|increases^expression	25607892
20	94-26-8	CACNA1C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA	affects^cotreatment\|affects^expression	25607892
21	94-26-8	CACNA1C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA	affects^cotreatment\|decreases^expression	25607892
22	94-26-8	CACNA1D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA	affects^cotreatment\|increases^expression	25607892
23	94-26-8	CACNA1D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA	affects^cotreatment\|increases^expression	25607892
24	94-26-8	CACNA1E	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA	affects^cotreatment\|decreases^expression	25607892
25	94-26-8	CACNA1F	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA	affects^cotreatment\|decreases^expression	25607892
26	94-26-8	CACNA1G	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA	affects^cotreatment\|decreases^expression	25607892
27	94-26-8	CACNA1G	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA	affects^cotreatment\|increases^expression	25607892
28	94-26-8	CACNA1H	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA	affects^cotreatment\|decreases^expression	25607892
29	94-26-8	CACNA1I	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA	affects^cotreatment\|decreases^expression	25607892
30	94-26-8	CACNA2D1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA	affects^cotreatment\|increases^expression	25607892
31	94-26-8	CACNA2D1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA	affects^cotreatment\|decreases^expression	25607892
32	94-26-8	CACNA2D2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA	affects^cotreatment\|increases^expression	25607892
33	94-26-8	CACNA2D2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA	affects^cotreatment\|increases^expression	25607892
34	94-26-8	CACNA2D3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA	affects^cotreatment\|affects^expression	25607892
35	94-26-8	CACNA2D3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA	affects^cotreatment\|increases^expression	25607892
36	94-26-8	CACNB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA	affects^cotreatment\|increases^expression	25607892
37	94-26-8	CACNB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	affects^cotreatment\|decreases^expression	25607892
38	94-26-8	CACNB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	affects^cotreatment\|increases^expression	25607892
39	94-26-8	CACNB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA	affects^cotreatment\|increases^expression	25607892
40	94-26-8	CACNB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA	affects^cotreatment\|increases^expression	25607892
41	94-26-8	CACNG2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA	affects^cotreatment\|increases^expression	25607892
42	94-26-8	CACNG5	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA	affects^cotreatment\|decreases^expression	25607892
43	94-26-8	CACNG6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA	affects^cotreatment\|decreases^expression	25607892
44	94-26-8	CACNG6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA	affects^cotreatment\|decreases^expression	25607892
45	94-26-8	CACNG8	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA	affects^cotreatment\|decreases^expression	25607892
46	94-26-8	CAMK2B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA	affects^cotreatment\|increases^expression	25607892
47	94-26-8	CASK	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA	affects^cotreatment\|affects^expression	25607892
48	94-26-8	CASK	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA	affects^cotreatment\|decreases^expression	25607892
49	94-26-8	CCND1	Homo sapiens	butylparaben results in increased expression of CCND1 mRNA	increases^expression	23524099
50	94-26-8	CD44	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA	affects^cotreatment\|decreases^expression	25607892
51	94-26-8	CD44	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA	affects^cotreatment\|decreases^expression	25607892
52	94-26-8	CEBPA	Homo sapiens	butylparaben results in increased expression of CEBPA mRNA	increases^expression	22956630
53	94-26-8	CEBPA	Mus musculus	2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]	decreases^reaction\|increases^expression	22956630
54	94-26-8	CEBPA	Mus musculus	2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]	decreases^reaction\|increases^expression	22956630
55	94-26-8	CEBPA	Mus musculus	butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]	increases^expression\|increases^reaction	22956630
56	94-26-8	CEBPA	Mus musculus	Mifepristone inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]	decreases^reaction\|increases^expression	22956630
57	94-26-8	CEBPA	Mus musculus	PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]	increases^expression\|increases^reaction	28527915
58	94-26-8	CEBPA	Mus musculus	rimonabant inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]	decreases^reaction\|increases^expression	27659731
59	94-26-8	CHRDL1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA	affects^cotreatment\|affects^expression	25607892
60	94-26-8	CNTN3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA	affects^cotreatment\|decreases^expression	25607892
61	94-26-8	CNTN4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA	affects^cotreatment\|decreases^expression	25607892
62	94-26-8	COL10A1	Mus musculus	butylparaben results in decreased expression of COL10A1 mRNA	decreases^expression	28527915
63	94-26-8	COL2A1	Mus musculus	butylparaben results in decreased expression of COL2A1 mRNA	decreases^expression	28527915
64	94-26-8	COPS2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA	affects^cotreatment\|decreases^expression	25607892
65	94-26-8	CYP11B1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA	affects^cotreatment\|decreases^expression	25607892
66	94-26-8	CYP17A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA	affects^cotreatment\|increases^expression	25607892
67	94-26-8	CYP19A1	Homo sapiens	butylparaben results in decreased expression of CYP19A1 mRNA	decreases^expression	23744433
68	94-26-8	CYP19A1	Homo sapiens	butylparaben results in decreased expression of CYP19A1 protein	decreases^expression	23744433
69	94-26-8	CYP19A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA	affects^cotreatment\|affects^expression	25607892
70	94-26-8	CYP19A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA	affects^cotreatment\|increases^expression	25607892
71	94-26-8	CYP1A1	Homo sapiens	[butylparaben co-treated with triclocarban] results in increased expression of CYP1A1 mRNA	affects^cotreatment\|increases^expression	23524099
72	94-26-8	CYP1A1	Rattus norvegicus	butylparaben results in decreased activity of CYP1A1 protein	decreases^activity	27432241
73	94-26-8	CYP1A2	Rattus norvegicus	butylparaben results in decreased activity of CYP1A2 protein	decreases^activity	27432241
74	94-26-8	CYP1B1	Homo sapiens	butylparaben promotes the reaction [bisphenol A results in increased expression of CYP1B1 mRNA]	increases^expression\|increases^reaction	23524099
75	94-26-8	CYP1B1	Homo sapiens	butylparaben results in increased expression of CYP1B1 mRNA	increases^expression	23524099
76	94-26-8	CYP2B1	Rattus norvegicus	butylparaben results in decreased activity of CYP2B1 protein	decreases^activity	27432241
77	94-26-8	CYP2C11	Rattus norvegicus	butylparaben results in decreased activity of CYP2C11 protein	decreases^activity	27432241
78	94-26-8	CYP2E1	Rattus norvegicus	butylparaben results in decreased activity of CYP2E1 protein	decreases^activity	27432241
79	94-26-8	CYP3A62	Rattus norvegicus	butylparaben results in decreased activity of CYP3A62 protein	decreases^activity	27432241
80	94-26-8	DCC	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA	affects^cotreatment\|decreases^expression	25607892
81	94-26-8	DLG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA	affects^cotreatment\|decreases^expression	25607892
82	94-26-8	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA	affects^cotreatment\|decreases^expression	25607892
83	94-26-8	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA	affects^cotreatment\|decreases^expression	25607892
84	94-26-8	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA	affects^cotreatment\|increases^expression	25607892
85	94-26-8	DLGAP3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA	affects^cotreatment\|increases^expression	25607892
86	94-26-8	DLGAP3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA	affects^cotreatment\|decreases^expression	25607892
87	94-26-8	DNMT3A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA	affects^cotreatment\|decreases^expression	25607892
88	94-26-8	DPP6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA	affects^cotreatment\|increases^expression	25607892
89	94-26-8	EGF	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA	affects^cotreatment\|decreases^expression	25607892
90	94-26-8	ERBB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA	affects^cotreatment\|decreases^expression	25607892
91	94-26-8	ERBB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA	affects^cotreatment\|decreases^expression	25607892
92	94-26-8	ERBB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA	affects^cotreatment\|decreases^expression	25607892
93	94-26-8	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA	affects^cotreatment\|affects^expression	25607892
94	94-26-8	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA	affects^cotreatment\|decreases^expression	25607892
95	94-26-8	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA	affects^cotreatment\|increases^expression	25607892
96	94-26-8	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA	affects^cotreatment\|decreases^expression	25607892
97	94-26-8	ESR1	Homo sapiens	butylparaben binds to and results in increased activity of ESR1 protein	affects^binding\|increases^activity	20362049\|20435135\|23567241\|25012808
98	94-26-8	ESR1	Homo sapiens	butylparaben binds to ESR1 protein	affects^binding	11193391\|19063592\|20074635
99	94-26-8	ESR1	Homo sapiens	[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]	affects^binding\|affects^cotreatment\|increases^reaction	26502914
100	94-26-8	ESR1	Homo sapiens	butylparaben results in decreased activity of ESR1 protein	decreases^activity	25012808
101	94-26-8	ESR1	Homo sapiens	butylparaben results in decreased expression of ESR1 mRNA	decreases^expression	23524099
102	94-26-8	ESR1	Homo sapiens	butylparaben results in increased activity of ESR1 protein	increases^activity	22562034
103	94-26-8	ESR1	Homo sapiens	butylparaben results in increased expression of ESR1 mRNA	increases^expression	25128701
104	94-26-8	ESR1	Homo sapiens	butylparaben results in increased expression of ESR1 protein	increases^expression	25128701
105	94-26-8	ESR1	Homo sapiens	fulvestrant inhibits the reaction [butylparaben results in increased activity of ESR1 protein]	decreases^reaction\|increases^activity	22562034
106	94-26-8	ESR1	Rattus norvegicus	butylparaben inhibits the reaction [Estradiol binds to ESR1 protein]	affects^binding\|decreases^reaction	15204698
107	94-26-8	ESR1	Rattus norvegicus	butylparaben results in decreased expression of ESR1 protein	decreases^expression	19654335
108	94-26-8	ESR1	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 mRNA]	decreases^expression\|decreases^reaction	19654335
109	94-26-8	ESR1	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 protein]	decreases^expression\|decreases^reaction	19654335
110	94-26-8	ESR2	Homo sapiens	butylparaben binds to and results in increased activity of ESR2 protein	affects^binding\|increases^activity	23567241
111	94-26-8	ESR2	Homo sapiens	butylparaben binds to ESR2 protein	affects^binding	11193391
112	94-26-8	ESR2	Homo sapiens	butylparaben results in increased expression of ESR2 mRNA	increases^expression	25128701
113	94-26-8	ESR2	Homo sapiens	butylparaben results in increased expression of ESR2 protein	increases^expression	25128701
114	94-26-8	ESR2	Rattus norvegicus	butylparaben results in decreased expression of ESR2 mRNA	decreases^expression	18648085
115	94-26-8	ESRRG	Homo sapiens	butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]]	affects^binding\|decreases^reaction	23583298
116	94-26-8	FAAH	Homo sapiens	butylparaben results in decreased activity of FAAH protein	decreases^activity	27659731
117	94-26-8	FABP4	Homo sapiens	butylparaben results in increased expression of FABP4 mRNA	increases^expression	22956630
118	94-26-8	FABP4	Mus musculus	butylparaben promotes the reaction [Dexamethasone results in increased expression of FABP4 mRNA]	increases^expression\|increases^reaction	22956630
119	94-26-8	FABP4	Mus musculus	NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]	increases^expression\|increases^reaction	28527915
120	94-26-8	FABP4	Mus musculus	PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]	decreases^reaction\|increases^expression	22956630
121	94-26-8	FABP4	Mus musculus	PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]	increases^expression\|increases^reaction	28527915
122	94-26-8	FASN	Homo sapiens	butylparaben results in increased expression of FASN mRNA	increases^expression	22956630
123	94-26-8	FASN	Mus musculus	butylparaben promotes the reaction [Dexamethasone results in increased expression of FASN mRNA]	increases^expression\|increases^reaction	22956630
124	94-26-8	FGFR1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA	affects^cotreatment\|decreases^expression	25607892
125	94-26-8	FGFR2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	affects^cotreatment\|decreases^expression	25607892
126	94-26-8	FYN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA	affects^cotreatment\|affects^expression	25607892
127	94-26-8	GABRA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA	affects^cotreatment\|decreases^expression	25607892
128	94-26-8	GABRB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA	affects^cotreatment\|decreases^expression	25607892
129	94-26-8	GLS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA	affects^cotreatment\|decreases^expression	25607892
130	94-26-8	GLS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA	affects^cotreatment\|decreases^expression	25607892
131	94-26-8	GPER1	Homo sapiens	butylparaben results in increased expression of GPER1 mRNA	increases^expression	26253279
132	94-26-8	GPER1	Homo sapiens	butylparaben results in increased expression of GPER1 protein	increases^expression	26253279
133	94-26-8	GRIA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA	affects^cotreatment\|decreases^expression	25607892
134	94-26-8	GRIA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA	affects^cotreatment\|decreases^expression	25607892
135	94-26-8	GRIA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA	affects^cotreatment\|decreases^expression	25607892
136	94-26-8	GRIK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	affects^cotreatment\|decreases^expression	25607892
137	94-26-8	GRIK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	affects^cotreatment\|increases^expression	25607892
138	94-26-8	GRIK4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA	affects^cotreatment\|decreases^expression	25607892
139	94-26-8	GRIK5	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA	affects^cotreatment\|increases^expression	25607892
140	94-26-8	GRIN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA	affects^cotreatment\|increases^expression	25607892
141	94-26-8	GRIN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA	affects^cotreatment\|increases^expression	25607892
142	94-26-8	GRIN2B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA	affects^cotreatment\|decreases^expression	25607892
143	94-26-8	GRIN2C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA	affects^cotreatment\|decreases^expression	25607892
144	94-26-8	GRIN2D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	affects^cotreatment\|decreases^expression	25607892
145	94-26-8	GRIN2D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	affects^cotreatment\|increases^expression	25607892
146	94-26-8	GRIN3A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA	affects^cotreatment\|decreases^expression	25607892
147	94-26-8	GRIP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA	affects^cotreatment\|decreases^expression	25607892
148	94-26-8	HES6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA	affects^cotreatment\|increases^expression	25607892
149	94-26-8	HR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA	affects^cotreatment\|decreases^expression	25607892
150	94-26-8	HSD17B10	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA	affects^cotreatment\|increases^expression	25607892
151	94-26-8	HSD17B8	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA	affects^cotreatment\|decreases^expression	25607892
152	94-26-8	HSD3B6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HSD3B6 mRNA	affects^cotreatment\|decreases^expression	25607892
153	94-26-8	HSPB8	Homo sapiens	butylparaben results in increased expression of HSPB8 mRNA	increases^expression	23524099
154	94-26-8	IGF1R	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA	affects^cotreatment\|increases^expression	25607892
155	94-26-8	IGF2R	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA	affects^cotreatment\|decreases^expression	25607892
156	94-26-8	IL1RAPL1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA	affects^cotreatment\|decreases^expression	25607892
157	94-26-8	JAG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA	affects^cotreatment\|increases^expression	25607892
158	94-26-8	LEP	Homo sapiens	butylparaben results in decreased expression of LEP mRNA	decreases^expression	22956630
159	94-26-8	LEP	Mus musculus	butylparaben results in increased expression of LEP mRNA	increases^expression	22956630
160	94-26-8	LIN7A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA	affects^cotreatment\|increases^expression	25607892
161	94-26-8	LPIN1	Mus musculus	butylparaben results in increased expression of LPIN1 mRNA	increases^expression	22956630
162	94-26-8	LPIN1	Mus musculus	[Dexamethasone co-treated with butylparaben] results in increased expression of LPIN1 mRNA	affects^cotreatment\|increases^expression	22956630
163	94-26-8	LPIN1	Mus musculus	NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA]	decreases^reaction\|increases^expression	22956630
164	94-26-8	MAGI2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA	affects^cotreatment\|decreases^expression	25607892
165	94-26-8	MAGI2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA	affects^cotreatment\|increases^expression	25607892
166	94-26-8	MDGA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA	affects^cotreatment\|decreases^expression	25607892
167	94-26-8	MDGA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA	affects^cotreatment\|increases^expression	25607892
168	94-26-8	MET	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA	affects^cotreatment\|increases^expression	25607892
169	94-26-8	MMP3	Rattus norvegicus	[enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA	affects^cotreatment\|increases^expression	25305543
170	94-26-8	MYC	Homo sapiens	butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]	increases^expression\|increases^reaction	26502914
171	94-26-8	MYC	Homo sapiens	butylparaben results in increased expression of MYC mRNA	increases^expression	26502914
172	94-26-8	MYC	Homo sapiens	[NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein	affects^cotreatment\|increases^expression	26502914
173	94-26-8	MYC	Homo sapiens	NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]	increases^expression\|increases^reaction	26502914
174	94-26-8	NF1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA	affects^cotreatment\|decreases^expression	25607892
175	94-26-8	NF1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA	affects^cotreatment\|decreases^expression	25607892
176	94-26-8	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA	affects^cotreatment\|increases^expression	25607892
177	94-26-8	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA	affects^cotreatment\|decreases^expression	25607892
178	94-26-8	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA	affects^cotreatment\|increases^expression	25607892
179	94-26-8	NOTCH2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA	affects^cotreatment\|increases^expression	25607892
180	94-26-8	NOTCH2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA	affects^cotreatment\|decreases^expression	25607892
181	94-26-8	NOTCH4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA	affects^cotreatment\|increases^expression	25607892
182	94-26-8	NOTCH4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA	affects^cotreatment\|decreases^expression	25607892
183	94-26-8	NR1I2.L	Xenopus laevis	butylparaben binds to and results in increased activity of NR1I2.L protein	affects^binding\|increases^activity	12198127
184	94-26-8	NR1I2.S	Xenopus laevis	butylparaben binds to and results in increased activity of NR1I2.S protein	affects^binding\|increases^activity	12198127
185	94-26-8	NR3C1	Homo sapiens	[butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein	affects^cotreatment\|increases^activity	25448277
186	94-26-8	NR3C1	Homo sapiens	butylparaben results in increased activity of NR3C1 protein	increases^activity	25448277
187	94-26-8	NR3C1	Homo sapiens	[Diethylhexyl Phthalate co-treated with butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein	affects^cotreatment\|increases^activity	25448277
188	94-26-8	NR3C1	Homo sapiens	[Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin co-treated with propylparaben] results in increased activity of NR3C1 protein	affects^cotreatment\|increases^activity	25448277
189	94-26-8	NR3C1	Homo sapiens	[Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin] results in increased activity of NR3C1 protein	affects^cotreatment\|increases^activity	25448277
190	94-26-8	NR3C1	Homo sapiens	[Diethylhexyl Phthalate co-treated with butylparaben] results in increased activity of NR3C1 protein	affects^cotreatment\|increases^activity	25448277
191	94-26-8	NR3C1	Mus musculus	NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]	decreases^expression\|increases^reaction	28527915
192	94-26-8	NR3C1	Mus musculus	NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]	increases^expression\|increases^reaction	28527915
193	94-26-8	NR3C1	Mus musculus	NR3C1 protein results in increased susceptibility to butylparaben	increases^response to substance	28527915
194	94-26-8	NR3C1		butylparaben promotes the reaction [Dexamethasone results in increased expression of NR3C1 mRNA]	increases^expression\|increases^reaction	22956630
195	94-26-8	NR3C2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA	affects^cotreatment\|increases^expression	25607892
196	94-26-8	NR5A1	Rattus norvegicus	butylparaben results in decreased expression of NR5A1 mRNA	decreases^expression	27122241
197	94-26-8	NRCAM	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA	affects^cotreatment\|increases^expression	25607892
198	94-26-8	NRG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA	affects^cotreatment\|decreases^expression	25607892
199	94-26-8	NRG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA	affects^cotreatment\|decreases^expression	25607892
200	94-26-8	NRXN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA	affects^cotreatment\|increases^expression	25607892
201	94-26-8	NRXN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA	affects^cotreatment\|increases^expression	25607892
202	94-26-8	NRXN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA	affects^cotreatment\|decreases^expression	25607892
203	94-26-8	NTRK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA	affects^cotreatment\|increases^expression	25607892
204	94-26-8	NTRK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA	affects^cotreatment\|decreases^expression	25607892
205	94-26-8	NTRK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA	affects^cotreatment\|increases^expression	25607892
206	94-26-8	NTRK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA	affects^cotreatment\|increases^expression	25607892
207	94-26-8	NTRK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA	affects^cotreatment\|increases^expression	25607892
208	94-26-8	NXPH3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA	affects^cotreatment\|decreases^expression	25607892
209	94-26-8	PGR	Homo sapiens	butylparaben results in increased expression of PGR mRNA	increases^expression	23524099\|25128701
210	94-26-8	PGR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA	affects^cotreatment\|decreases^expression	25607892
211	94-26-8	PGR	Rattus norvegicus	butylparaben results in increased expression of PGR protein	increases^expression	19654335
212	94-26-8	PGR	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR mRNA]	decreases^reaction\|increases^expression	19654335
213	94-26-8	PGR	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR protein]	decreases^reaction\|increases^expression	19654335
214	94-26-8	PLIN1	Mus musculus	butylparaben results in increased expression of PLIN1 mRNA	increases^expression	22956630
215	94-26-8	PLIN1	Mus musculus	PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]	decreases^reaction\|increases^expression	22956630
216	94-26-8	PLIN1	Mus musculus	PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]	increases^expression\|increases^reaction	28527915
217	94-26-8	PPARG	Homo sapiens	butylparaben binds to and results in increased activity of PPARG protein	affects^binding\|increases^activity	24155963
218	94-26-8	PPARG	Homo sapiens	butylparaben results in increased expression of PPARG mRNA	increases^expression	22956630
219	94-26-8	PPARG	Mus musculus	2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]	decreases^reaction\|increases^expression	22956630
220	94-26-8	PPARG	Mus musculus	2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]	decreases^reaction\|increases^expression	22956630
221	94-26-8	PPARG	Mus musculus	butylparaben promotes the reaction [Dexamethasone results in increased expression of PPARG mRNA]	increases^expression\|increases^reaction	22956630
222	94-26-8	PPARG	Mus musculus	butylparaben results in increased activity of PPARG protein	increases^activity	28527915
223	94-26-8	PPARG	Mus musculus	Mifepristone inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]	decreases^reaction\|increases^expression	22956630
224	94-26-8	PPARG	Mus musculus	PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA]	decreases^expression\|decreases^reaction	28527915
225	94-26-8	PPARG	Mus musculus	PPARG protein promotes the reaction [butylparaben binds to and results in increased activity of PPARG protein]	affects^binding\|increases^activity\|increases^reaction	24155963
226	94-26-8	PPARG	Mus musculus	PPARG protein results in increased susceptibility to butylparaben	increases^response to substance	28527915
227	94-26-8	PRKN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA	affects^cotreatment\|decreases^expression	25607892
228	94-26-8	PRKN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA	affects^cotreatment\|decreases^expression	25607892
229	94-26-8	RELN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA	affects^cotreatment\|decreases^expression	25607892
230	94-26-8	ROBO1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA	affects^cotreatment\|decreases^expression	25607892
231	94-26-8	RUNX2	Mus musculus	butylparaben results in decreased expression of RUNX2 mRNA	decreases^expression	28527915
232	94-26-8	S100G	Rattus norvegicus	butylparaben results in increased expression of S100G mRNA	increases^expression	19654335
233	94-26-8	S100G	Rattus norvegicus	butylparaben results in increased expression of S100G protein	increases^expression	19654335
234	94-26-8	S100G	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G mRNA]	decreases^reaction\|increases^expression	19654335
235	94-26-8	S100G	Rattus norvegicus	fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G protein]	decreases^reaction\|increases^expression	19654335
236	94-26-8	SHANK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA	affects^cotreatment\|increases^expression	25607892
237	94-26-8	SHANK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA	affects^cotreatment\|increases^expression	25607892
238	94-26-8	SHANK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA	affects^cotreatment\|decreases^expression	25607892
239	94-26-8	SHANK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA	affects^cotreatment\|decreases^expression	25607892
240	94-26-8	SHANK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA	affects^cotreatment\|increases^expression	25607892
241	94-26-8	SLC17A7	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA	affects^cotreatment\|increases^expression	25607892
242	94-26-8	SLC1A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA	affects^cotreatment\|increases^expression	25607892
243	94-26-8	SLC1A2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA	affects^cotreatment\|increases^expression	25607892
244	94-26-8	SLC1A3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA	affects^cotreatment\|increases^expression	25607892
245	94-26-8	SLC1A3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA	affects^cotreatment\|increases^expression	25607892
246	94-26-8	SLC1A6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA	affects^cotreatment\|increases^expression	25607892
247	94-26-8	SLIT1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA	affects^cotreatment\|decreases^expression	25607892
248	94-26-8	SLIT1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA	affects^cotreatment\|increases^expression	25607892
249	94-26-8	SPP1	Mus musculus	butylparaben results in decreased expression of SPP1 mRNA	decreases^expression	28527915
250	94-26-8	SPTBN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA	affects^cotreatment\|decreases^expression	25607892
251	94-26-8	STAR	Rattus norvegicus	butylparaben results in decreased expression of STAR mRNA	decreases^expression	18648085
252	94-26-8	STMN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA	affects^cotreatment\|increases^expression	25607892
253	94-26-8	STS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA	affects^cotreatment\|decreases^expression	25607892
254	94-26-8	STS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA	affects^cotreatment\|decreases^expression	25607892
255	94-26-8	STX1B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA	affects^cotreatment\|increases^expression	25607892
256	94-26-8	STXBP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA	affects^cotreatment\|increases^expression	25607892
257	94-26-8	STXBP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA	affects^cotreatment\|increases^expression	25607892
258	94-26-8	SYNGAP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA	affects^cotreatment\|decreases^expression	25607892
259	94-26-8	SYP	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA	affects^cotreatment\|increases^expression	25607892
260	94-26-8	SYT6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA	affects^cotreatment\|decreases^expression	25607892
261	94-26-8	TFF1	Homo sapiens	butylparaben results in increased expression of TFF1 mRNA	increases^expression	16797915\|22562034\|23524099
262	94-26-8	TFF1	Homo sapiens	fulvestrant inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA]	decreases^reaction\|increases^expression	22562034
263	94-26-8	TGFB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA	affects^cotreatment\|decreases^expression	25607892
264	94-26-8	TSC2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA	affects^cotreatment\|increases^expression	25607892
265	94-26-8	TSC2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA	affects^cotreatment\|increases^expression	25607892
266	94-26-8	TSNAX	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA	affects^cotreatment\|decreases^expression	25607892
267	94-26-8	TSPO	Rattus norvegicus	butylparaben results in decreased expression of TSPO mRNA	decreases^expression	18648085
268	94-26-8	UGT2B15	Homo sapiens	butylparaben results in increased expression of UGT2B15 mRNA	increases^expression	23524099
269	94-26-8	UNC5A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA	affects^cotreatment\|decreases^expression	25607892
270	94-26-8	UNC5B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA	affects^cotreatment\|decreases^expression	25607892
271	94-26-8	UNC5C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA	affects^cotreatment\|increases^expression	25607892
272	94-26-8	UNC5C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA	affects^cotreatment\|increases^expression	25607892
273	94-26-8	VEGFA	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA	affects^cotreatment\|increases^expression	25607892
274	94-26-8	VLDLR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA	affects^cotreatment\|decreases^expression	25607892

Serial No.	Activity Name	Details	References (PubMed)	Other details EPA (U.S)	Clinical Trials (U.S. NIH)
1				94-26-8	Butyl 4-hydroxybenzoate

Print Back

Compound Image

2D Structure

Download

Download Sdf File Download PDB File Download MOL File

View Similar Structures (External DB)

AromaDb: A Database of Plant's Aroma Molecules

AROMA: A Database of Plant's Aroma Molecules